aluates Reports

$ 0.0

Automative

Global IL-17 Inhibitors for Psoriasis Market Research Report 2024

Published Date: October 2024

Report Code: QYRE-Auto-11M18622

BUY CHAPTERS

Global IL-17 Inhibitors for Psoriasis Market Research Report 2024

Code: QYRE-Auto-11M18622

Report

October 2024

Pages:78

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

UCB

Eli Lilly

Novartis

Ortho Dermatologics

LEO Pharma

Kyowa Kirin

Jiangsu Hengrui Pharmaceuticals

Chongqing Genrix Biopharmaceutical

IL-17 Inhibitors for Psoriasis Market

IL-17 inhibitors for psoriasis are a class of biologic drugs designed to target and block the activity of interleukin-17 (IL-17), a pro-inflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. By inhibiting IL-17, these drugs reduce the excessive immune response and help control the symptoms of moderate to severe plaque psoriasis. Examples of IL-17 inhibitors include secukinumab, ixekizumab, brodalumab and so on.

The global IL-17 Inhibitors for Psoriasis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.

North American market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of IL-17 Inhibitors for Psoriasis include UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, Kyowa Kirin, Jiangsu Hengrui Pharmaceuticals, Chongqing Genrix Biopharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for IL-17 Inhibitors for Psoriasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IL-17 Inhibitors for Psoriasis.

The IL-17 Inhibitors for Psoriasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global IL-17 Inhibitors for Psoriasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the IL-17 Inhibitors for Psoriasis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of IL-17 Inhibitors for Psoriasis Market Report

Report Metric	Details
Report Name	IL-17 Inhibitors for Psoriasis Market
Segment by Type	Bimelizumab Secukinumab Ixekizumab Brodalumab Vunakizumab Xeligekimab Other
Segment by Application	Hospital and Clinic Pharmacy Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, Kyowa Kirin, Jiangsu Hengrui Pharmaceuticals, Chongqing Genrix Biopharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of IL-17 Inhibitors for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of IL-17 Inhibitors for Psoriasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the IL-17 Inhibitors for Psoriasis Market report?

Ans: The main players in the IL-17 Inhibitors for Psoriasis Market are UCB, Eli Lilly, Novartis, Ortho Dermatologics, LEO Pharma, Kyowa Kirin, Jiangsu Hengrui Pharmaceuticals, Chongqing Genrix Biopharmaceutical

What are the Application segmentation covered in the IL-17 Inhibitors for Psoriasis Market report?

Ans: The Applications covered in the IL-17 Inhibitors for Psoriasis Market report are Hospital and Clinic, Pharmacy, Other

What are the Type segmentation covered in the IL-17 Inhibitors for Psoriasis Market report?

Ans: The Types covered in the IL-17 Inhibitors for Psoriasis Market report are Bimelizumab, Secukinumab, Ixekizumab, Brodalumab, Vunakizumab, Xeligekimab, Other

Recommended Reports

Dermatology Therapeutics

Immune Modulating Drugs

Skin Disease Treatments

1 IL-17 Inhibitors for Psoriasis Market Overview

1.1 Product Definition

1.2 IL-17 Inhibitors for Psoriasis by Type

1.2.1 Global IL-17 Inhibitors for Psoriasis Market Value Comparison by Type (2024-2030)

1.2.2 Bimelizumab

1.2.3 Secukinumab

1.2.4 Ixekizumab

1.2.5 Brodalumab

1.2.6 Vunakizumab

1.2.7 Xeligekimab

1.2.8 Other

1.3 IL-17 Inhibitors for Psoriasis by Application

1.3.1 Global IL-17 Inhibitors for Psoriasis Market Value by Application (2024-2030)

1.3.2 Hospital and Clinic

1.3.3 Pharmacy

1.3.4 Other

1.4 Global IL-17 Inhibitors for Psoriasis Market Size Estimates and Forecasts

1.4.1 Global IL-17 Inhibitors for Psoriasis Revenue 2019-2030

1.4.2 Global IL-17 Inhibitors for Psoriasis Sales 2019-2030

1.4.3 Global IL-17 Inhibitors for Psoriasis Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 IL-17 Inhibitors for Psoriasis Market Competition by Manufacturers

2.1 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Manufacturers (2019-2024)

2.2 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2019-2024)

2.3 Global IL-17 Inhibitors for Psoriasis Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of IL-17 Inhibitors for Psoriasis, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of IL-17 Inhibitors for Psoriasis, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of IL-17 Inhibitors for Psoriasis, Product Type & Application

2.7 Global Key Manufacturers of IL-17 Inhibitors for Psoriasis, Date of Enter into This Industry

2.8 Global IL-17 Inhibitors for Psoriasis Market Competitive Situation and Trends

2.8.1 Global IL-17 Inhibitors for Psoriasis Market Concentration Rate

2.8.2 The Global 5 and 10 Largest IL-17 Inhibitors for Psoriasis Players Market Share by Revenue

2.8.3 Global IL-17 Inhibitors for Psoriasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global IL-17 Inhibitors for Psoriasis Market Scenario by Region

3.1 Global IL-17 Inhibitors for Psoriasis Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2019-2030

3.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2019-2024

3.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2025-2030

3.3 Global IL-17 Inhibitors for Psoriasis Revenue by Region: 2019-2030

3.3.1 Global IL-17 Inhibitors for Psoriasis Revenue by Region: 2019-2024

3.3.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region: 2025-2030

3.4 North America IL-17 Inhibitors for Psoriasis Market Facts & Figures by Country

3.4.1 North America IL-17 Inhibitors for Psoriasis Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America IL-17 Inhibitors for Psoriasis Sales by Country (2019-2030)

3.4.3 North America IL-17 Inhibitors for Psoriasis Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe IL-17 Inhibitors for Psoriasis Market Facts & Figures by Country

3.5.1 Europe IL-17 Inhibitors for Psoriasis Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2019-2030)

3.5.3 Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific IL-17 Inhibitors for Psoriasis Market Facts & Figures by Region

3.6.1 Asia Pacific IL-17 Inhibitors for Psoriasis Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific IL-17 Inhibitors for Psoriasis Sales by Region (2019-2030)

3.6.3 Asia Pacific IL-17 Inhibitors for Psoriasis Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America IL-17 Inhibitors for Psoriasis Market Facts & Figures by Country

3.7.1 Latin America IL-17 Inhibitors for Psoriasis Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America IL-17 Inhibitors for Psoriasis Sales by Country (2019-2030)

3.7.3 Latin America IL-17 Inhibitors for Psoriasis Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Facts & Figures by Country

3.8.1 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2019-2030)

3.8.3 Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global IL-17 Inhibitors for Psoriasis Sales by Type (2019-2030)

4.1.1 Global IL-17 Inhibitors for Psoriasis Sales by Type (2019-2024)

4.1.2 Global IL-17 Inhibitors for Psoriasis Sales by Type (2025-2030)

4.1.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2019-2030)

4.2 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2019-2030)

4.2.1 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2019-2024)

4.2.2 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2025-2030)

4.2.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2019-2030)

4.3 Global IL-17 Inhibitors for Psoriasis Price by Type (2019-2030)

5 Segment by Application

5.1 Global IL-17 Inhibitors for Psoriasis Sales by Application (2019-2030)

5.1.1 Global IL-17 Inhibitors for Psoriasis Sales by Application (2019-2024)

5.1.2 Global IL-17 Inhibitors for Psoriasis Sales by Application (2025-2030)

5.1.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2019-2030)

5.2 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2019-2030)

5.2.1 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2019-2024)

5.2.2 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2025-2030)

5.2.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2019-2030)

5.3 Global IL-17 Inhibitors for Psoriasis Price by Application (2019-2030)

6 Key Companies Profiled

6.1 UCB

6.1.1 UCB Company Information

6.1.2 UCB Description and Business Overview

6.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.1.4 UCB IL-17 Inhibitors for Psoriasis Product Portfolio

6.1.5 UCB Recent Developments/Updates

6.2 Eli Lilly

6.2.1 Eli Lilly Company Information

6.2.2 Eli Lilly Description and Business Overview

6.2.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio

6.2.5 Eli Lilly Recent Developments/Updates

6.3 Novartis

6.3.1 Novartis Company Information

6.3.2 Novartis Description and Business Overview

6.3.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Novartis IL-17 Inhibitors for Psoriasis Product Portfolio

6.3.5 Novartis Recent Developments/Updates

6.4 Ortho Dermatologics

6.4.1 Ortho Dermatologics Company Information

6.4.2 Ortho Dermatologics Description and Business Overview

6.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio

6.4.5 Ortho Dermatologics Recent Developments/Updates

6.5 LEO Pharma

6.5.1 LEO Pharma Company Information

6.5.2 LEO Pharma Description and Business Overview

6.5.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.5.4 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio

6.5.5 LEO Pharma Recent Developments/Updates

6.6 Kyowa Kirin

6.6.1 Kyowa Kirin Company Information

6.6.2 Kyowa Kirin Description and Business Overview

6.6.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio

6.6.5 Kyowa Kirin Recent Developments/Updates

6.7 Jiangsu Hengrui Pharmaceuticals

6.7.1 Jiangsu Hengrui Pharmaceuticals Company Information

6.7.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview

6.7.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio

6.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

6.8 Chongqing Genrix Biopharmaceutical

6.8.1 Chongqing Genrix Biopharmaceutical Company Information

6.8.2 Chongqing Genrix Biopharmaceutical Description and Business Overview

6.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio

6.8.5 Chongqing Genrix Biopharmaceutical Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 IL-17 Inhibitors for Psoriasis Industry Chain Analysis

7.2 IL-17 Inhibitors for Psoriasis Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 IL-17 Inhibitors for Psoriasis Production Mode & Process

7.4 IL-17 Inhibitors for Psoriasis Sales and Marketing

7.4.1 IL-17 Inhibitors for Psoriasis Sales Channels

7.4.2 IL-17 Inhibitors for Psoriasis Distributors

7.5 IL-17 Inhibitors for Psoriasis Customers

8 IL-17 Inhibitors for Psoriasis Market Dynamics

8.1 IL-17 Inhibitors for Psoriasis Industry Trends

8.2 IL-17 Inhibitors for Psoriasis Market Drivers

8.3 IL-17 Inhibitors for Psoriasis Market Challenges

8.4 IL-17 Inhibitors for Psoriasis Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

UCB

Eli Lilly

Novartis

Ortho Dermatologics

LEO Pharma

Kyowa Kirin

Jiangsu Hengrui Pharmaceuticals

Chongqing Genrix Biopharmaceutical

List of Tables

Table 1. Global IL-17 Inhibitors for Psoriasis Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global IL-17 Inhibitors for Psoriasis Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global IL-17 Inhibitors for Psoriasis Market Competitive Situation by Manufacturers in 2023

Table 4. Global IL-17 Inhibitors for Psoriasis Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Manufacturers (2019-2024)

Table 6. Global IL-17 Inhibitors for Psoriasis Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global IL-17 Inhibitors for Psoriasis Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market IL-17 Inhibitors for Psoriasis Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of IL-17 Inhibitors for Psoriasis, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of IL-17 Inhibitors for Psoriasis, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of IL-17 Inhibitors for Psoriasis, Product Type & Application

Table 12. Global Key Manufacturers of IL-17 Inhibitors for Psoriasis, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global IL-17 Inhibitors for Psoriasis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IL-17 Inhibitors for Psoriasis as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global IL-17 Inhibitors for Psoriasis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global IL-17 Inhibitors for Psoriasis Sales by Region (2019-2024) & (K Units)

Table 18. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2019-2024)

Table 19. Global IL-17 Inhibitors for Psoriasis Sales by Region (2025-2030) & (K Units)

Table 20. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2025-2030)

Table 21. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2019-2024)

Table 23. Global IL-17 Inhibitors for Psoriasis Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2025-2030)

Table 25. North America IL-17 Inhibitors for Psoriasis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America IL-17 Inhibitors for Psoriasis Sales by Country (2019-2024) & (K Units)

Table 27. North America IL-17 Inhibitors for Psoriasis Sales by Country (2025-2030) & (K Units)

Table 28. North America IL-17 Inhibitors for Psoriasis Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America IL-17 Inhibitors for Psoriasis Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe IL-17 Inhibitors for Psoriasis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2019-2024) & (K Units)

Table 32. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2025-2030) & (K Units)

Table 33. Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe IL-17 Inhibitors for Psoriasis Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific IL-17 Inhibitors for Psoriasis Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific IL-17 Inhibitors for Psoriasis Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific IL-17 Inhibitors for Psoriasis Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific IL-17 Inhibitors for Psoriasis Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific IL-17 Inhibitors for Psoriasis Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America IL-17 Inhibitors for Psoriasis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America IL-17 Inhibitors for Psoriasis Sales by Country (2019-2024) & (K Units)

Table 42. Latin America IL-17 Inhibitors for Psoriasis Sales by Country (2025-2030) & (K Units)

Table 43. Latin America IL-17 Inhibitors for Psoriasis Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2019-2024) & (K Units)

Table 47. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2025-2030) & (K Units)

Table 48. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global IL-17 Inhibitors for Psoriasis Sales (K Units) by Type (2019-2024)

Table 51. Global IL-17 Inhibitors for Psoriasis Sales (K Units) by Type (2025-2030)

Table 52. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2019-2024)

Table 53. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2025-2030)

Table 54. Global IL-17 Inhibitors for Psoriasis Revenue (US$ Million) by Type (2019-2024)

Table 55. Global IL-17 Inhibitors for Psoriasis Revenue (US$ Million) by Type (2025-2030)

Table 56. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2019-2024)

Table 57. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2025-2030)

Table 58. Global IL-17 Inhibitors for Psoriasis Price (US$/Unit) by Type (2019-2024)

Table 59. Global IL-17 Inhibitors for Psoriasis Price (US$/Unit) by Type (2025-2030)

Table 60. Global IL-17 Inhibitors for Psoriasis Sales (K Units) by Application (2019-2024)

Table 61. Global IL-17 Inhibitors for Psoriasis Sales (K Units) by Application (2025-2030)

Table 62. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2019-2024)

Table 63. Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2025-2030)

Table 64. Global IL-17 Inhibitors for Psoriasis Revenue (US$ Million) by Application (2019-2024)

Table 65. Global IL-17 Inhibitors for Psoriasis Revenue (US$ Million) by Application (2025-2030)

Table 66. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2019-2024)

Table 67. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2025-2030)

Table 68. Global IL-17 Inhibitors for Psoriasis Price (US$/Unit) by Application (2019-2024)

Table 69. Global IL-17 Inhibitors for Psoriasis Price (US$/Unit) by Application (2025-2030)

Table 70. UCB Company Information

Table 71. UCB Description and Business Overview

Table 72. UCB IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. UCB IL-17 Inhibitors for Psoriasis Product

Table 74. UCB Recent Developments/Updates

Table 75. Eli Lilly Company Information

Table 76. Eli Lilly Description and Business Overview

Table 77. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Eli Lilly IL-17 Inhibitors for Psoriasis Product

Table 79. Eli Lilly Recent Developments/Updates

Table 80. Novartis Company Information

Table 81. Novartis Description and Business Overview

Table 82. Novartis IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Novartis IL-17 Inhibitors for Psoriasis Product

Table 84. Novartis Recent Developments/Updates

Table 85. Ortho Dermatologics Company Information

Table 86. Ortho Dermatologics Description and Business Overview

Table 87. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product

Table 89. Ortho Dermatologics Recent Developments/Updates

Table 90. LEO Pharma Company Information

Table 91. LEO Pharma Description and Business Overview

Table 92. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. LEO Pharma IL-17 Inhibitors for Psoriasis Product

Table 94. LEO Pharma Recent Developments/Updates

Table 95. Kyowa Kirin Company Information

Table 96. Kyowa Kirin Description and Business Overview

Table 97. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product

Table 99. Kyowa Kirin Recent Developments/Updates

Table 100. Jiangsu Hengrui Pharmaceuticals Company Information

Table 101. Jiangsu Hengrui Pharmaceuticals Description and Business Overview

Table 102. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product

Table 104. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates

Table 105. Chongqing Genrix Biopharmaceutical Company Information

Table 106. Chongqing Genrix Biopharmaceutical Description and Business Overview

Table 107. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product

Table 109. Chongqing Genrix Biopharmaceutical Recent Developments/Updates

Table 110. Key Raw Materials Lists

Table 111. Raw Materials Key Suppliers Lists

Table 112. IL-17 Inhibitors for Psoriasis Distributors List

Table 113. IL-17 Inhibitors for Psoriasis Customers List

Table 114. IL-17 Inhibitors for Psoriasis Market Trends

Table 115. IL-17 Inhibitors for Psoriasis Market Drivers

Table 116. IL-17 Inhibitors for Psoriasis Market Challenges

Table 117. IL-17 Inhibitors for Psoriasis Market Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

Table 121. Authors List of This Report

List of Figures

Figure 1. Product Picture of IL-17 Inhibitors for Psoriasis

Figure 2. Global IL-17 Inhibitors for Psoriasis Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global IL-17 Inhibitors for Psoriasis Market Share by Type: 2023 & 2030

Figure 4. Bimelizumab Product Picture

Figure 5. Secukinumab Product Picture

Figure 6. Ixekizumab Product Picture

Figure 7. Brodalumab Product Picture

Figure 8. Vunakizumab Product Picture

Figure 9. Xeligekimab Product Picture

Figure 10. Other Product Picture

Figure 11. Global IL-17 Inhibitors for Psoriasis Market Value by Application (2024-2030) & (US$ Million)

Figure 12. Global IL-17 Inhibitors for Psoriasis Market Share by Application: 2023 & 2030

Figure 13. Hospital and Clinic

Figure 14. Pharmacy

Figure 15. Other

Figure 16. Global IL-17 Inhibitors for Psoriasis Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 17. Global IL-17 Inhibitors for Psoriasis Market Size (2019-2030) & (US$ Million)

Figure 18. Global IL-17 Inhibitors for Psoriasis Sales (2019-2030) & (K Units)

Figure 19. Global IL-17 Inhibitors for Psoriasis Average Price (US$/Unit) & (2019-2030)

Figure 20. IL-17 Inhibitors for Psoriasis Report Years Considered

Figure 21. IL-17 Inhibitors for Psoriasis Sales Share by Manufacturers in 2023

Figure 22. Global IL-17 Inhibitors for Psoriasis Revenue Share by Manufacturers in 2023

Figure 23. Global 5 and 10 Largest IL-17 Inhibitors for Psoriasis Players: Market Share by Revenue in IL-17 Inhibitors for Psoriasis in 2023

Figure 24. IL-17 Inhibitors for Psoriasis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 25. Global IL-17 Inhibitors for Psoriasis Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 26. North America IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2019-2030)

Figure 27. North America IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2019-2030)

Figure 28. United States IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Canada IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2019-2030)

Figure 31. Europe IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2019-2030)

Figure 32. Germany IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. France IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. U.K. IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Italy IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Russia IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Asia Pacific IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2019-2030)

Figure 38. Asia Pacific IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2019-2030)

Figure 39. China IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Japan IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. South Korea IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. India IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Australia IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. China Taiwan IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Southeast Asia IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Latin America IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2019-2030)

Figure 47. Mexico IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Colombia IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2019-2030)

Figure 52. Middle East and Africa IL-17 Inhibitors for Psoriasis Revenue Market Share by Country (2019-2030)

Figure 53. Turkey IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Saudi Arabia IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. UAE IL-17 Inhibitors for Psoriasis Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Global Sales Market Share of IL-17 Inhibitors for Psoriasis by Type (2019-2030)

Figure 57. Global Revenue Market Share of IL-17 Inhibitors for Psoriasis by Type (2019-2030)

Figure 58. Global IL-17 Inhibitors for Psoriasis Price (US$/Unit) by Type (2019-2030)

Figure 59. Global Sales Market Share of IL-17 Inhibitors for Psoriasis by Application (2019-2030)

Figure 60. Global Revenue Market Share of IL-17 Inhibitors for Psoriasis by Application (2019-2030)

Figure 61. Global IL-17 Inhibitors for Psoriasis Price (US$/Unit) by Application (2019-2030)

Figure 62. IL-17 Inhibitors for Psoriasis Value Chain

Figure 63. IL-17 Inhibitors for Psoriasis Production Process

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Interleukin 17 Inhibitors Market Research Report 2024

Global IL 17 Targeting Biological Drugs Market Research Report 2024

Global Secukinumab Market Research Report 2024

Global TNF Inhibitors for the Treatment of Plaque Psoriasis Market Research Report 2024

Global Monoclonal Antibodies for Plaque Psoriasis Market Research Report 2024

Global IL 17 Monoclonal Antibody Injections Market Research Report 2024

Global Biologic Medications for Psoriasis Market Research Report 2024

Global IL 23 Receptor Antagonist Market Research Report 2024

Global Psoriasis Biosimilar Market Research Report 2024

Global Interleukin 6 Inhibitors for Rheumatoid Arthritis Market Research Report 2024

Global Biopharmaceuticals for Psoriasis Market Research Report 2024

Global Plaque Psoriasis Treatment Medications Market Research Report 2024

Global Psoriasis Therapeutics Market Insights Forecast to 2030

Global Oral JAK Inhibitors Market Research Report 2024

Global IL 23p19 Inhibitors Market Research Report 2024

Global Psoriasis Biologics Drugs Market Research Report 2025

Global IL 6R Inhibitor Market Research Report 2024

Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Insights Forecast to 2030

Global IL 2R Inhibitors Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions